Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Poolbeg Pharma (POLB) Competitors

Poolbeg Pharma logo
GBX 4.90 0.00 (0.00%)
As of 05/18/2026 11:02 AM Eastern
Compare

POLB vs. TILS, VSN, MPH, BVXP, and FARN

Should you buy Poolbeg Pharma stock or one of its competitors? MarketBeat compares Poolbeg Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Poolbeg Pharma include Tiziana Life Sciences (TILS), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), Bioventix (BVXP), and Faron Pharmaceuticals Oy (FARN). These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for Poolbeg Pharma and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Poolbeg Pharma
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Summary

Poolbeg Pharma beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Poolbeg Pharma (LON:POLB) and Verseon (LON:VSN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Verseon N/A N/A N/A

In the previous week, Poolbeg Pharma had 4 more articles in the media than Verseon. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Verseon. Verseon's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Verseon is being referred to more favorably in the news media.

Company Overall Sentiment
Poolbeg Pharma Neutral
Verseon Neutral

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
VerseonN/AN/AN/A-£14.30N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Poolbeg Pharma and Verseon tied by winning 4 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Poolbeg Pharma N/A -55.47%-21.33%

In the previous week, Poolbeg Pharma had 4 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Mereo BioPharma Group plc (MPH.L) is being referred to more favorably in the media.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Poolbeg Pharma Neutral

Summary

Mereo BioPharma Group plc (MPH.L) and Poolbeg Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Bioventix?

Poolbeg Pharma (LON:POLB) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, Poolbeg Pharma had 3 more articles in the media than Bioventix. MarketBeat recorded 4 mentions for Poolbeg Pharma and 1 mentions for Bioventix. Bioventix's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Bioventix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Poolbeg Pharma
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bioventix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bioventix has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
Bioventix£12.54M6.96£8.12M£140.5211.89

Poolbeg Pharma has a beta of 1.819, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.484, meaning that its stock price is 52% less volatile than the broader market.

1.5% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 21.1% of Bioventix shares are owned by institutional investors. 7.6% of Poolbeg Pharma shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Poolbeg Pharma's net margin of 0.00%. Bioventix's return on equity of 65.83% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
Bioventix 59.30%65.83%54.07%

Summary

Bioventix beats Poolbeg Pharma on 9 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Faron Pharmaceuticals Oy has a beta of 1.109, indicating that its share price is 11% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.819, indicating that its share price is 82% more volatile than the broader market.

In the previous week, Poolbeg Pharma had 4 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 4 mentions for Poolbeg Pharma and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Poolbeg Pharma Neutral

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Poolbeg Pharma N/A -55.47%-21.33%

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Summary

Faron Pharmaceuticals Oy and Poolbeg Pharma tied by winning 5 of the 10 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

POLB vs. The Competition

Export
MetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£34.55M£461.09M£6.25B£2.76B
Dividend YieldN/A3.86%2.80%6.15%
P/E Ratio-5.213.8620.86365.85
Price / SalesN/A7,677.36550.9188,116.34
Price / Cash2.1113.1327.4827.89
Price / Book0.0083.139.677.62
Net Income-£4.50B-£96.07M£3.56B£5.89B
7 Day Performance8.89%-0.01%-1.69%0.42%
1 Month Performance7.69%-0.72%-2.65%0.56%
1 Year Performance73.94%68.78%30.03%84.41%

Poolbeg Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
N/AGBX 4.90
flat		N/A+69.6%£34.55MN/AN/A12
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
BVXP
Bioventix
N/AGBX 1,677
-1.4%		N/A-40.3%£87.62M£12.54M11.9312

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel